Type 2 Diabetes Mellitus and Vertebral Fracture Risk

Purpose of Review The purpose of this review is to summarize the recently published evidence concerning vertebral fracture risk in individuals with diabetes mellitus. Recent Findings Vertebral fracture risk is increased in individuals with T2DM. The presence of vertebral fractures in T2DM is associated with increased non-vertebral fracture risk and mortality. TBS could be helpful to estimate vertebral fracture risk in individuals with T2DM. An increased amount of bone marrow fat has been implicated in bone fragility in T2DM. Results from two recent studies show that both teriparatide and denosumab are effective in reducing vertebral fracture risk also in individuals with T2DM. Summary Individuals with T2DM could benefit from systematic screening in the clinic for presence of vertebral fractures.

Automated summary

Recent studies have shown that vertebral fracture risk is increased in individuals with type 2 diabetes mellitus, and is associated with higher risk of non-vertebral fractures and mortality. An increased amount of bone marrow fat may contribute to bone fragility in T2DM. Both teriparatide and denosumab have been found effective in reducing vertebral fracture risk in individuals with T2DM.